Progenics Pharmaceuticals Inc. (PGNX) financial statements (2022 and earlier)

Company profile

Business Address ONE WORLD TRADE CENTER
NEW YORK, NY 10007
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29,53142,04964,49384,823109,587137,686148,851
Cash and cash equivalents29,53142,04964,49384,823109,587137,686148,851
Receivables6,19015,9766,17410,5694,9353,8035,821
Other current assets4,8255,7075,1364,8063,1252,6402,237
Total current assets:40,54663,73275,803100,198117,647144,129156,909
Noncurrent Assets
Operating lease, right-of-use asset13,27913,49313,68113,88913,293
Property, plant and equipment14,67311,6889,2547,0086,0623,9443,977
Intangible assets, net (including goodwill)24,39424,67024,94625,22225,49819,74019,967
Goodwill17,84717,84717,84717,84717,84713,07413,074
Intangible assets, net (excluding goodwill)6,5476,8237,0997,3757,6516,6666,893
Restricted cash and investments      1,529
Other noncurrent assets5,4525,8876,3686,4641,7041,684 
Total noncurrent assets:57,79855,73854,24952,58346,55725,36825,473
TOTAL ASSETS:98,344119,470130,052152,781164,204169,497182,382
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,24314,35213,13517,21010,06810,9778,279
Accounts payable2,8601,249674272564444629
Accrued liabilities8,38313,10312,46116,9389,50410,5337,650
Debt7,2407,7167,0096,3616,4785,4198,216
Business combination, contingent consideration, liability    7,9007,050 
Other undisclosed current liabilities616      
Total current liabilities:19,09922,06820,14423,57124,44623,44616,495
Noncurrent Liabilities
Long-term debt and lease obligation44,99846,91549,64351,65452,35539,18038,332
Long-term debt, excluding current maturities30,16631,91034,48936,34237,56839,18038,332
Operating lease, liability14,83215,00515,15415,31214,787
Liabilities, other than long-term debt3,6343,9344,3004,8004,0005,76812,646
Deferred income tax liabilities3434   
Other liabilities     1,8181,746
Business combination, contingent consideration, liability3,6003,9004,3004,8004,0003,95010,900
Other undisclosed noncurrent liabilities  2828282826
Total noncurrent liabilities:48,63250,84953,97156,48256,38344,97651,004
Total liabilities:67,73172,91774,11580,05380,82968,42267,499
Stockholders' equity
Stockholders' equity attributable to parent30,61346,55355,93772,72883,375101,075114,883
Common stock113113112112110110110
Treasury stock, value(2,741)(2,741)(2,741)(2,741)(2,741)(2,741)(2,741)
Common stock, share subscribed but unissued, subscriptions receivable   (933)   
Additional paid in capital728,129727,089725,356724,027714,096713,019712,111
Accumulated other comprehensive loss(327)(148)(305)(94)(147)(105)(93)
Accumulated deficit(694,561)(677,760)(666,485)(647,643)(627,943)(609,208)(594,504)
Total stockholders' equity:30,61346,55355,93772,72883,375101,075114,883
TOTAL LIABILITIES AND EQUITY:98,344119,470130,052152,781164,204169,497182,382

Income statement (P&L) ($ in thousands)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Revenues6,24815,1265,6139,9664,2813,2385,317
Cost of revenue(1,558)(958)(1,317)(493)   
Cost of goods and services sold(1,558)(1,358)(1,317)(493)   
Gross profit:4,69014,1684,2969,4734,2813,2385,317
Operating expenses(20,876)(24,883)(22,912)(29,059)(22,516)(17,790)(30,365)
Other undisclosed operating income300 500493   
Operating loss:(15,886)(10,715)(18,116)(19,093)(18,235)(14,552)(25,048)
Nonoperating expense(915)(543)(726)(607)(500)(235)(762)
Loss from continuing operations before income taxes:(16,801)(11,258)(18,842)(19,700)(18,735)(14,787)(25,810)
Income tax benefit     831,453
Other undisclosed loss from continuing operations (17)     
Net loss available to common stockholders, diluted:(16,801)(11,275)(18,842)(19,700)(18,735)(14,704)(24,357)

Comprehensive Income ($ in thousands)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Net loss:(16,801)(11,275)(18,842)(19,700)(18,735)(14,704)(24,357)
Other undisclosed comprehensive loss     (72) 
Comprehensive loss:(16,801)(11,275)(18,842)(19,700)(18,735)(14,776)(24,357)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(179)157(211)53(42)60(4)
Comprehensive loss, net of tax, attributable to parent:(16,980)(11,118)(19,053)(19,647)(18,777)(14,716)(24,361)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: